Light AI Inc. (OHCFF)

Light AI Inc. is a healthcare technology company developing a software-as-medical-device platform that applies artificial intelligence to smartphone camera images to identify infectious diseases and medical conditions in seconds. The company trades on the OTCQB under the ticker OHCFF and is headquartered in Vancouver, British Columbia. It represents an unusual capital structure for a medical technology venture: a company burning through early-stage development funding while racing to demonstrate that AI applied to ubiquitous consumer hardware—the smartphone—can reliably detect what normally requires swabs, blood tests, and laboratory infrastructure.

The founding insight was straightforward: four and a half billion smartphones exist globally, each with a capable camera. If an artificial intelligence algorithm could be trained to read visual signs of disease in photographs, the friction and cost of diagnosis could collapse. No proprietary hardware to purchase, no supply chains to manage, no patient travel to clinics. Just an app that a person opens when they suspect illness, aims their phone’s camera, and waits seconds for a result. That frictionless design is the company’s core premise.

Light AI began with focused early development on diagnosing Group A Streptococcus—a bacterial infection that causes strep throat, scarlet fever, and other illnesses. The natural next steps were built into the roadmap: COVID-19 diagnosis from cough and respiratory symptoms, then expansion into other conditions where visual or symptom-based assessment could accelerate diagnosis.

The path from laboratory proof-of-concept to commercially deployed diagnostic tool is deliberately long and expensive. Light AI has been working through clinical trials and regulatory submission processes in its target markets, with regulatory bodies treating the technology as a medical device even though it is purely software. That classification raises the bar for approval but also creates the opportunity for meaningful regulatory moats once cleared. If Light AI’s algorithms can gain clearance in major markets—particularly the United States, where the FDA would review the submission—the company could move from a research-stage operation to a deployed product with contracted relationships and revenue.

As of the middle of 2026, Light AI had not yet begun the commercial phase. The company remains in the clinical and regulatory stage, with formal commercialization anticipated in the second half of 2026 if approvals land on schedule. That timing makes the company a binary bet: either the trials, the regulatory submissions, and the commercial partnerships all converge and begin to generate meaningful revenue, or any of those steps falters and extends the runway further.

The capital picture reflects that stage. Light AI has been operating on a small war chest, with cash of roughly four to five million dollars in recent quarters—enough to fund operations but not enough for prolonged commercialization without revenue or additional capital. The company has not yet demonstrated whether it can raise capital easily, whether hospitals and clinics will actually adopt the technology, or whether the regulatory agencies that oversee medical diagnostics will prove easier or harder to satisfy than the company’s current timeline implies.

What sets Light AI apart in the early-stage medtech world is its radical simplification of the business model. Almost every other diagnostic startup is trying to build proprietary hardware, negotiate supply chains, and convince customers to buy equipment. Light AI is instead betting on ubiquity and software. If the bet works—if the algorithms truly work and regulators permit their deployment—the leverage could be extraordinary because the incremental cost to add a new diagnosis to the platform is the cost of training the algorithm, not the cost of designing and manufacturing hardware. But that leverage only appears if the company gets to commercialization.

For someone studying this company, the key documents are the Form 10-K filings with the SEC (CIK 0001735514), which lay out the cash burn rate, the regulatory milestones, and the commercial assumptions management is working toward. The quarterly and annual updates are the place to watch for news on clinical trial progress, regulatory feedback from agencies, and any partnerships or pilot programs with medical facilities. The single most important metric is the timing and outcome of regulatory submissions—not financial revenue or user growth, but the regulatory event that says whether the core premise actually works or whether the technology is facing headwinds that extend the road to deployment by years.

Light AI is instructive as a pure-play capital allocation problem. The company is spending cash on R&D and regulatory work in the hope of proving a technology that, if successful, could be deployed at near-zero incremental cost to millions of patients. That is the leverage the founders are chasing. Until the regulatory and commercial inflection points arrive, the company is a story of whether the bet pays off or whether it runs out of runway before the inflection points arrive.